HPV感染重型宫颈病变患者应用LEEP联合重组人干扰素α-2b栓治疗的效果评价
|
摘要
目的探讨人乳头状瘤病毒(HPV)感染重型宫颈病变患者应用宫颈环形电切术(LEEP)联合重组人干扰素α-2b栓治疗的应用价值。方法选取2016年12月至2017年12月间于佛山市口腔医院诊治的HPV感染重型宫颈病变患者78例,按随机数字法分为对照组和观察组,其中采用LEEP术治疗的患者39例(对照组),采用LEEP术联合重组人干扰素α-2b栓治疗的患者39例(观察组)。比较两组临床疗效、HPV转阴率、围术期指标和并发症情况。结果观察组的治愈率及有效率、治疗后12周HPV转阴率均高于对照组,观察组患者复发率明显低于对照组;观察组患者术后创面愈合时间、阴道出血时间及阴道渗液时间均少于对照组;观察组术后并发症发生率明显低于对照组。以上对比均有统计学意义(p<0.05)。结论应用LEEP联合重组人干扰素α-2b栓治疗HPV感染重型宫颈病变可提升疗效,减少阴道出血和渗液,促进切口愈合,减少并发症,降低复发率,值得在临床应用中推广。
0 bjective To explore the application value of loop electrosurgical excisional procedure(LEEP)combined with recombinant human interferon α-2 b suppository in patients with severe cervical lesions infected by human papillomavirus(HPV). Methods 78 patients with severe cervical lesions infected with HPV from December 2016 to December 2017 were divided into the control group and the observation group according to the random number method, of which 39 cases(control group) were treated with LEEP, and 39 patients(observation group) were treated with LEEP combined with recombinant human interferon α-2 b suppository.The clinical efficacy, HPV negative rate, perioperative indicators and complications were compared between the two groups. Results The cure rate, the effective rate and the negative rate of HPV for 12 weeks after treatment of the observation group were all higher than that of the control group, and the recurrence rate of the patients in the observation group was significantly lower than that of the control group. The healing time of wound surface, the time of vaginal bleeding and the time of vaginal exudation in the observation group were less than those of the control group. And the incidence of postoperative complications in the observation group was significantly lower than that of the control group. The above contrasts were statistically significant(p<0.05). Conclusion The application of LEEP combined with recombinant human interferon α-2b suppository in the treatment of severe cervical lesions with HPV infection can improve the curative effect, reduce vaginal bleeding and exudation,promote the healing of the incision, reduce the complications and reduce the recurrence rate. It is worth popularizing in clinical application.
0 bjective To explore the application value of loop electrosurgical excisional procedure(LEEP)combined with recombinant human interferon α-2 b suppository in patients with severe cervical lesions infected by human papillomavirus(HPV). Methods 78 patients with severe cervical lesions infected with HPV from December 2016 to December 2017 were divided into the control group and the observation group according to the random number method, of which 39 cases(control group) were treated with LEEP, and 39 patients(observation group) were treated with LEEP combined with recombinant human interferon α-2 b suppository.The clinical efficacy, HPV negative rate, perioperative indicators and complications were compared between the two groups. Results The cure rate, the effective rate and the negative rate of HPV for 12 weeks after treatment of the observation group were all higher than that of the control group, and the recurrence rate of the patients in the observation group was significantly lower than that of the control group. The healing time of wound surface, the time of vaginal bleeding and the time of vaginal exudation in the observation group were less than those of the control group. And the incidence of postoperative complications in the observation group was significantly lower than that of the control group. The above contrasts were statistically significant(p<0.05). Conclusion The application of LEEP combined with recombinant human interferon α-2b suppository in the treatment of severe cervical lesions with HPV infection can improve the curative effect, reduce vaginal bleeding and exudation,promote the healing of the incision, reduce the complications and reduce the recurrence rate. It is worth popularizing in clinical application.
引文
[1]季雯婷.人乳头瘤病毒与宫颈病变的研究进展[J].国际妇产科学杂志,2013,40(2):138-141.
[2]张宏伟,隋龙.液基细胞学技术在宫颈病变筛查的应用现状及不足[J].中国计划生育和妇产科,2013,5(1):20-23.
[3]刘淑芬.LEEP治疗宫颈病变218例临床观察[J].中国医学创新,2013,10(4):94-95.
[4]韩淑琴,刘俊霞,李晓兵,等.重组人干扰素α-2b阴道泡腾胶囊联合甘露聚糖肽治疗女性尖锐湿疣的临床研究[J].河北医药,2014,36(13):1952-1953.
[5]徐小卫. LEEP联合重组人干扰素α-2b栓治疗宫颈糜烂临床疗效观察[J].中国妇幼保健, 2013, 28(14):2311-2313.
[6]何国梅. LEEP刀联合重组人干扰素α-2b栓治疗HPV感染重型宫颈病变的临床疗效[J].中国生育健康杂志, 2017, 28(2):164-167.
[7]杨燕芬,邱毅,佟雁,等. HPV多重感染与宫颈病变的关系研究[J].中国妇幼保健, 2016, 31(2):254-256.
[8]常小垒,郭科军,张颐. HPV亚型与子宫颈癌前病变及癌变的关系探讨[J].中国医科大学学报, 2014, 43(8):720-723.
[9]盛薪潼. LEEP治疗宫颈病变的效果研究[J].中国医药指南, 2017, 15(11):45-46.
[10]徐华,闫素文,徐斌.宫颈上皮内瘤变2级两种治疗方式的临床研究[J].中国妇产科临床杂志, 2013, 14(1):23-25.
[11]胡爱勤,王金华.重组人干扰素α-2b阴道泡腾胶囊治疗宫颈人乳头瘤病毒感染的临床研究[J].中国临床药理学杂志,2015, 31(4):259-260+263.
[12]梅泉,杨慧.重组人干扰素α-2b阴道泡腾胶囊在宫颈环形电切术后的应用[J].上海医药, 2015, 36(10):20-22.
[13]陈丽霞.宫颈环形电切术联合重组人干扰素α-2b栓治疗宫颈上皮内瘤样病变临床分析[J].中国医学前沿杂志(电子版), 2015, 7(7):46-48.
[14]胡亚莉.宫颈电圈环切术结合重组人干扰素α-2b凝胶治疗重度宫颈糜烂的疗效[J].现代医药卫生, 2014(16):2471-2473.
[15]梁皓,胡丽娜. LEEP术后宫颈并发症及妊娠结局的临床分析[J].中外医疗, 2015, 34(9):23-25.
[2]张宏伟,隋龙.液基细胞学技术在宫颈病变筛查的应用现状及不足[J].中国计划生育和妇产科,2013,5(1):20-23.
[3]刘淑芬.LEEP治疗宫颈病变218例临床观察[J].中国医学创新,2013,10(4):94-95.
[4]韩淑琴,刘俊霞,李晓兵,等.重组人干扰素α-2b阴道泡腾胶囊联合甘露聚糖肽治疗女性尖锐湿疣的临床研究[J].河北医药,2014,36(13):1952-1953.
[5]徐小卫. LEEP联合重组人干扰素α-2b栓治疗宫颈糜烂临床疗效观察[J].中国妇幼保健, 2013, 28(14):2311-2313.
[6]何国梅. LEEP刀联合重组人干扰素α-2b栓治疗HPV感染重型宫颈病变的临床疗效[J].中国生育健康杂志, 2017, 28(2):164-167.
[7]杨燕芬,邱毅,佟雁,等. HPV多重感染与宫颈病变的关系研究[J].中国妇幼保健, 2016, 31(2):254-256.
[8]常小垒,郭科军,张颐. HPV亚型与子宫颈癌前病变及癌变的关系探讨[J].中国医科大学学报, 2014, 43(8):720-723.
[9]盛薪潼. LEEP治疗宫颈病变的效果研究[J].中国医药指南, 2017, 15(11):45-46.
[10]徐华,闫素文,徐斌.宫颈上皮内瘤变2级两种治疗方式的临床研究[J].中国妇产科临床杂志, 2013, 14(1):23-25.
[11]胡爱勤,王金华.重组人干扰素α-2b阴道泡腾胶囊治疗宫颈人乳头瘤病毒感染的临床研究[J].中国临床药理学杂志,2015, 31(4):259-260+263.
[12]梅泉,杨慧.重组人干扰素α-2b阴道泡腾胶囊在宫颈环形电切术后的应用[J].上海医药, 2015, 36(10):20-22.
[13]陈丽霞.宫颈环形电切术联合重组人干扰素α-2b栓治疗宫颈上皮内瘤样病变临床分析[J].中国医学前沿杂志(电子版), 2015, 7(7):46-48.
[14]胡亚莉.宫颈电圈环切术结合重组人干扰素α-2b凝胶治疗重度宫颈糜烂的疗效[J].现代医药卫生, 2014(16):2471-2473.
[15]梁皓,胡丽娜. LEEP术后宫颈并发症及妊娠结局的临床分析[J].中外医疗, 2015, 34(9):23-25.